<h4>Background</h4>Myc rearrangement (Myc-R) is a controversial factor linked to adverse outcomes in newly diagnosed multiple myeloma (NDMM).<h4>Aims</h4>This study aimed to evaluate the impact of Myc-R on the prognosis of NDMM patients and its role in risk stratification compared with traditional high-risk cytogenetic abnormalities (HRCAs).<h4>Materials & methods</h4>A total of 417 NDMM patients enrolled from May 2009 to September 2022 were included. Here, MYC is linked to AL amyloidosis.